Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Biotechnology 27, 883–885 (1 October 2009) | doi:10.1038/nbt1009-883
Credibility: your most important asset
&
Abstract
What do you think sells your company to the outside world? A promising pipeline? A stellar founding team? A solid intellectual property (IP) portfolio? Those things won't hurt, but credibility may be the most important asset for a startup biotech company (and a public biotech company for that matter). Credibility is your best weapon when facing pipeline delays, regulatory rejections, IP challenges and all the other inevitable issues that are part of a biotech venture.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
